ArticleBMC nephrology2026
Efficacy of immunosuppressive therapy in low-risk and intermediate- risk idiopathic membranous nephropathy patients : a 2-year follow-up study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy and safety of immunosuppressive therapy for low- and intermediate-risk idiopathic membranous nephropathy (IMN) remain unclear.
methodA total of 117 renal biopsy-confirmed idiopathic membranous nephropathy (IMN) patients were retrospectively enrolled from the Department of Nephrology, First Affiliated Hospital of USTC (2021-2023). Participants were stratified by baseline urinary protein-to-creatinine ratio (uPCR): low-risk group (≤ 3.0 g/gCr) vs. intermediate-risk group (> 3.0 g/gCr). The low-risk group included 57 patients, 26 of whom received immunosuppressive agents after a minimum of 3 months of supportive care due to persistent proteinuria. All remaining patients initiated immunosuppressive therapy at enrollment. Total remission rates (TRR, including complete remission rate [CRR] and partial remission rate [PRR]) and CRR were compared at 6, 12, and 24 months, with infectious events documented. Binary logistic regression identified risk factors for remission.
resultsA total of 117 IMN patients were stratified into low-risk (n = 57) and intermediate-risk (n = 60) groups. During the 2-year follow-up, the low-risk group exhibited significantly higher complete remission rates than the intermediate-risk group at 6 months (P < 0.01), 12 months (P < 0.01), and 24 months (P = 0.01). No significant between-group differences in total remission rates were observed at any time point. Binary logistic regression revealed intermediate-risk classification as an independent risk factor for non-remission across all follow-up points (6, 12, and 24 months; all P < 0.05). Male sex was positively associated with complete remission (CR) only at 12 months (OR = 3.24, P = 0.04), whereas no significant associations were detected at 6 and 24 months. Serum triglyceride levels, anti-PLA2R antibody status, and specific immunosuppressive regimens showed no significant correlations with CR at any follow-up time point (all P > 0.05). The overall incidence of infections was comparable between the two groups (P > 0.05), and no deaths occurred throughout follow-up.
conclusionAn observational association was identified between early immunosuppressive therapy and higher CRRs at all follow-up time points in patients with low-risk IMN, with no marked elevation in infectious risk observed. However, this correlation cannot be interpreted as definitive therapeutic benefit due to major confounding factors including unassessed spontaneous remission and absence of a supportive-care-only control group. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.